Steve Ross

Prolight Diagnostics’ CTO highlights the potential of the Psyros system

BioStock talked to Steve Ross, co-founder of Psyros Diagnostics, which was acquired by Prolight Diagnostics in 2022. He and the other co-founders play a...
Enzymatica

Enzymatica’s partners await MDR certification and study results

Enzymatica has published its year-end report, revealing an operating result of SEK -48.1 million and net sales of SEK 50.9 million for the full...
BiBBInstruments utökar patentskyddet till Japan

BiBBInstruments expands patent protection to Japan

BiBBInstruments’ electric-driven biopsy instrument for advanced endoscopy, EndoDrill, has been market cleared in Europe and the US. The Swedish medtech is clearly aiming to...
Prolight Diagnostics goals

Prolight Diagnostics CEO: “We deliver on all goals”

Prolight Diagnostics' year-end report for 2023 shows that the company met all the goals for the year. The company's point-of-care analysis system has shown...
Adjutec prepares for clinical trial

Adjutec applies for phase I start

Norwegian AdjuTec Pharma prepares for clinical trials with its concept for battling antimicrobial resistance. The company recently raised 16 MNOK and sent a clinical...
Ultimovacs receives Orphan Drug Designation from EMA

Ultimovacs receives Orphan Drug Designation from EMA

Ultimovacs has been granted Orphan Drug Designation from the European Medicines Agency for its universal cancer vaccine, UV1, as a treatment for mesothelioma, a...
Start

PHI: “We aim to revolutionize the regenerative medicine market “

A year ago, Patrik Eschricht assumed the role of CEO at PHI, heralding the shift towards regenerative medicine and a commitment to enhancing shareholder...
Alligator prepares for phase III with CD40 agonist

Alligator prepares for phase III with CD40 agonist

Having met the primary endpoint in its OPTIMIZE-1 phase II trial with mitazalimab in pancreatic cancer, Alligator Bioscience can now start preparing for phase...
Medivir_CEO_Q&A

Medivir’s CEO comments on the latest developments

As Medivir reports its fourth quarter, the company’s focus is on the further improved clinical efficacy of fostrox in combination with Lenvima in liver...
Full speed ahead for Elicera in 2024

Full speed ahead for Elicera in 2024

Elicera Therapeutics has kicked off the year in boost mode. The Swedish cell and gene therapy company will get moving on the newly approved...